secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2025-03-19T23:59:59+00:00
Accession:  0001493152-25-010868
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir-1 reduces tumor size ~50% in prostate cancer model; protects against chemo toxicity
--------------------------------------------------------------------------------

- Telomir-1 alone (low and high doses) reduced tumor growth ~50% in aggressive human prostate cancer animal model.
- Contrary to concerns, Telomir-1 suppressed tumor development and selectively benefited healthy cells.
- Paclitaxel alone caused severe toxicity with one-third mortality; adding low-dose Telomir-1 eliminated mortality.
- Telomir-1 combined with Paclitaxel neutralized chemotherapy-induced toxicity and weight loss.
- Results position Telomir-1 as a potential adjunct to standard chemotherapy for prostate cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000149315225010868/0001493152-25-010868-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000149315225010868/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-010868

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer